Standout Papers

Pathological findings of COVID-19 associated with acute respiratory distress syndrome 2020 2026 2022 20245.8k
  1. Pathological findings of COVID-19 associated with acute respiratory distress syndrome (2020)
    Zhe Xu, Lei Shi et al. The Lancet Respiratory Medicine
  2. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial (2022)
    Sattva S. Neelapu, Michael Dickinson et al. Nature Medicine

Immediate Impact

2 by Nobel laureates 22 from Science/Nature 59 standout
Sub-graph 1 of 21

Citing Papers

CAR T Cells and T-Cell Therapies for Cancer
2024 Standout
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
2024 Standout
4 intermediate papers

Works of Jinghui Dong being referenced

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
2022 Standout
Abstract CT055: Phase 1/2 primary analysis of ZUMA-6: Axicabtagene ciloleucel (Axi-Cel) in combination With atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL)
2020

Author Peers

Author Last Decade Papers Cites
Jinghui Dong 997 76 587 4495 2402 37 6.6k
Li Zhu 753 85 704 4373 2301 50 6.6k
Yijin Wang 722 234 689 4286 2265 50 6.4k
Lei Huang 705 42 540 4255 2261 29 6.0k
Changqing Bai 666 43 618 4383 2272 43 6.7k
Yanhong Tai 980 58 606 4216 2263 44 6.9k
Jin‐Wen Song 721 81 644 4316 2263 62 6.5k
Zhe Xu 935 155 668 4435 2326 82 7.0k
Minghao Fang 1150 20 879 5058 2762 29 7.4k
Xiaojing Zou 1158 49 965 4857 2621 47 7.5k
Shangwen Pan 1095 16 847 4668 2551 29 7.1k

All Works

Loading papers...

Rankless by CCL
2026